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ABSTRACT:
The purpose of the present study was to elucidate the transport
mechanisms responsible for elimination of micafungin, a new
semisynthetic echinocandin antifungal agent, which is predomi-
nantly cleared by biliary excretion in humans and rats. In vitro
studies using sandwich-cultured rat and human hepatocytes were
conducted. Micafungin uptake occurred primarily (75%) by trans-
porter-mediated mechanisms in rat and human. Micafungin uptake
into hepatocytes was inhibited by taurocholate (Ki  61 M), Na

depletion (45–55% reduced), and 10 M rifampin (20–25% reduced);
these observations support the involvement of Na-taurocholate-
cotransporting polypeptide (NTCP/Ntcp) and, to a lesser extent, or-
ganic anion-transporting polypeptides in the hepatic uptake of mica-
fungin. The in vitro biliary clearance of micafungin, as measured by
the B-CLEAR technique, amounted to 14 and 19 l/(min  mg protein)
in human and rat, respectively. In vitro biliary excretion of micafungin
was reduced by 80 and 75% in the presence of the bile salt export
pump (BSEP) inhibitors taurocholate (100 M) and nefazodone (25
M), respectively. Biliary excretion of micafungin also was reduced in
the presence of breast cancer resistance protein inhibitors [N-(4-[2-
(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-
dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) (10
M) and fumitremorgin C (10 M)]. In vitro biliary excretion of mica-
fungin was not significantly altered by coincubation with P-
glycoprotein or multidrug resistance-associated protein 2 inhibitors.
These results suggest that NTCP/Ntcp and BSEP/Bsep are primarily
responsible for hepatobiliary disposition of micafungin in human and
rat. Interference with hepatic bile acid disposition could be one mech-
anism underlying hepatotoxicity associated with micafungin in some
patients.
Introduction
Micafungin is a new semisynthetic echinocandin-type antifungal
drug with activity against both Candida and Aspergillus species that
relies on inhibition of -1,3-glucan synthesis to exert its therapeutic
effect. Because -1,3-glucan is a unique but essential component of
the fungal cell wall, micafungin has a superior activity/toxicity profile
compared with the polyene antifungal drug amphotericin B, with less
drug interactions than the azole antimycotic drugs. Pharmacokinetic
studies with [14C]micafungin demonstrated that approximately 90%
of the plasma clearance occurs via biliary elimination of the parent
and minor metabolites (Hebert et al., 2005a), whereas urinary excre-
tion is a minor elimination route in humans and rats (Kaneko et al.,
2002; Yamato et al., 2002; Carver, 2004). Like caspofungin and
anidulafungin, micafungin is a peptide-like compound. Because of the
presence of a sulfate group, micafungin is negatively charged at
physiological pH (Fig. 1). Micafungin displays high plasma protein
binding (99%) in humans and animals (Carver, 2004).
Mechanisms underlying the hepatobiliary disposition of micafungin
in humans remain to be elucidated. Drug-drug interaction studies in
humans and in rats have been useful but not sufficient to support our
understanding of its disposition in human populations. Sakaeda et al.
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(2005) reported that micafungin is not a substrate or inhibitor for
human P-glycoprotein (P-gp) in a multidrug resistance 1-overexpress-
ing cell line. Clinical studies by Hebert et al. (2005a,b) showed that
cyclosporine A significantly increased micafungin exposure (AUC),
whereas tacrolimus had no effect. In rats, intravenous administration
of cyclosporine A reduced the systemic clearance, volume of distri-
bution at steady state, and the biliary clearance of micafungin. In a
recent study, Abe et al. (2008b) reported a role for multidrug resis-
tance-associated protein 2 (Mrp2, Abcc2) in the biliary excretion of
micafungin in the rat. These authors demonstrated that micafungin
biliary clearance was significantly decreased (by 60%) in Eisai
hyperbilirubinemic Mrp2-deficient rats [TR(/)] compared with
wild-type animals.
On the basis of clinical and preclinical data, the chemical structure,
and physicochemical properties of micafungin, it is our hypothesis
that micafungin hepatobiliary clearance is mediated by hepatic drug
uptake transporters such as those belonging to the organic anion-
transporting polypeptide (OATP, SLCO) family and/or the Na-
taurocholate-cotransporting polypeptide (NTCP/Ntcp, SLC10A1) and
by one or more of the following efflux transporters on the canalicular
membrane: 1) MRP2/Mrp2 (ABCC2/Abcc2); 2) breast cancer resis-
tance protein (BCRP/Bcrp, ABCG2/Abcg2); and 3) bile salt export
pump (BSEP/Bsep, ABCB11/Abcb11). The in vitro studies performed
with sandwich-cultured hepatocytes in the present study demonstrate
that NTCP and BSEP play a major role in the hepatobiliary disposi-
tion of micafungin.
Materials and Methods
Chemicals and Reagents. Micafungin sodium was a gift from Dr. John
Perfect at Duke University. [3H]Taurocholic acid (5 Ci/mmol) was obtained from
PerkinElmer Life and Analytical Sciences (Waltham, MA). Choline chloride,
collagenase (type IV), dexamethasone, fumitremorgin C, 3-[[3-[2-(7-chloroquino-
lin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propi-
onic acid (MK571), nefazodone, rifampin, and taurocholic acid were purchased
from Sigma-Aldrich (St. Louis, MO). N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-
2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carbox-
amide (GF120918, Elacridar) was a gift from GlaxoSmithKline (Uxbridge, Mid-
dlesex, UK), whereas 5(and 6)-carboxy-2,7-dichlorofluorescein diacetate
(CDFDA) was purchased from Invitrogen (Carlsbad, CA). ITS (insulin, trans-
ferrin, selenious acid, and linoleic acid bound to bovine serum albumin) culture
supplement and BioCoat plates were purchased from BD Biosciences Discovery
Labware (Bedford, MA). Williams’ E medium or Dulbecco’s modified Eagle’s
medium, fetal bovine serum, penicillin G sodium, and streptomycin sulfate,
modified essential medium nonessential amino acids, and l-glutamine were ob-
tained from Invitrogen. Standard buffer (Plus buffer) consisted of Hanks’ balanced
salt solution containing 10 mM Hepes and was adjusted to pH 7.4. Ca2-free
buffer (Minus buffer) consisted of Ca2/Mg2-free Hanks’ balanced salt solution
containing 1 mM EGTA and 10 mM Hepes and was adjusted to pH 7.4. Na-free
buffer consisted of 140 mM choline chloride, 10 mM Hepes, 1 mM CaCl2, 1 mM
MgSO4, 10 mM Tris, 5 mM KCl, and 5 mM glucose.
Animals. Male Wistar rats (240–300 g) were used for hepatocyte preparations.
Animals had free access to water and food before surgery. All animal procedures
complied with the guidelines of the Institutional Animal Care and Use Committee
(Katholieke Universiteit Leuven and University of North Carolina at Chapel Hill).
TR(/) Wistar rats (206–346 g) originating from the breeding stock obtained
from Dr. Mary Vore (University of Kentucky, Lexington, KY) were bred at the
University of North Carolina (Chapel Hill, NC) and were used for hepatocyte
preparations by the Cellular and Metabolism and Transport Core Facility at the
University of North Carolina Eshelman School of Pharmacy.
Preparation of Sandwich-Cultured Human and Rat Hepatocytes.
Freshly isolated human hepatocytes from three liver donors were used. The
following donor data were available: donor 1, 16-year-old white male; donor
2, 42-year-old white female; and donor 3, 36-year-old white male. Hepatocytes
were isolated by CellzDirect (Durham, NC), plated in 24-well BioCoat culture
plates overlaid with Matrigel, and cultured at 37°C in a humidified incubator
with 95% O2-5% CO2 in serum-free Williams’ E medium supplemented with
gentamicin, dexamethasone, ITS culture supplement, l-glutamine, and
Hepes. Medium was changed every day until the transport studies were
conducted. For rat hepatocytes, cell isolation was achieved by using a two-step
collagenase perfusion as described previously (Abe et al., 2008c; Ye et al.,
2008), and viability was 90% with a yield of 4 to 6  108 cells/liver. After
isolation, hepatocytes were seeded in 12-well plates at 1 million cells/well and
cultured as described previously by Ye et al. (2008).
Uptake Study. Day 1 sandwich-cultured rat hepatocytes (SCRH) or day 6
sandwich-cultured human hepatocytes (SCHH) were used to measure micaf-
ungin uptake. Hepatocytes (three wells per condition) were preincubated with
1 ml/well (12-well plate) or 0.5 ml/well (24-well plate) of standard buffer for
10 min at 37°C, followed by another 10-min preincubation in the absence
(control) or in the presence of rifampin (10 M), taurocholate (100 M), or
Na-free/choline buffer (prepared as described by Su et al., 2004). In parallel,
cells were incubated with standard buffer at 4°C. Subsequently, micafungin
(10 M) was added to all inhibitor-treated cells or untreated cells (control) to
initiate uptake for 10 min (previously determined to be linear). After the
incubation, cells were rinsed three times with 1 ml/well of ice-cold standard
buffer. After rinsing, micafungin was extracted from hepatocytes by shaking
the plates for 20 min at room temperature after addition of 1 ml of 10% formic
acid in acetonitrile (v/v) containing 1 M diclofenac as analytical internal
standard. The extracted micafungin samples were centrifuged for 10 min at
10,000 rpm (14,000g), and supernatant was dried under air before reconstitu-
tion in 0.5 ml of 10% acetonitrile-containing 5% formic acid (v/v). Aliquots
(100 l) were analyzed for quantitative determination of micafungin using
high-performance liquid chromatography (HPLC) coupled with fluorescence
and ultraviolet detection. Uptake was normalized to the protein content of the
hepatocytes, determined in at least three separate wells by lysing the hepato-
cytes in these wells with 0.5 ml/well of 0.5% Triton X-100 solution and
analyzing the cell lysate by the bicinchoninic acid method using bovine serum
albumin as standard (0.2–1.0 mg/ml). All uptake data were corrected for
nonspecific binding to collagen-coated, hepatocyte-free culture wells.
Concentration-dependent inhibition of [3H]taurocholate (2.5 M) or mica-
fungin (10 M) uptake by micafungin or taurocholate, respectively, was
measured by treating the sandwich-cultured rat hepatocytes with taurocholate
(0–200 M) or micafungin (0–500 M) in the presence of the other. After a
10-min incubation with the putative inhibitor, accumulated micafungin was
extracted and quantitatively determined as described above, and accumulated
[3H]taurocholate was determined after lysing hepatocytes with 0.5 ml of 0.5%
Triton X-100 solution and analyzing cell lysates by liquid scintillation spec-
trometry (LS50B; PerkinElmer Life and Analytical Sciences). Corresponding
IC50 values were estimated according to eq. 1 from the best fit to substrate
uptake data as a percentage of no inhibitor control versus inhibitor concentra-
tions by using WinNonlin software.
The kinetics of micafungin uptake in day 1 SCRH or day 6 SCHH were
measured by incubating hepatocytes with 1 to 500 M micafungin for 10 min,
and processing samples as described above. The best fits to micafungin uptake
data were obtained by nonlinear regression analysis using WinNonlin to
determine the kinetic parameters for the saturable (Michaelis-Menten: Km and
Vmax) and nonsaturable (Cld) uptake according to eq. 2 (see Data Analysis).
FIG. 1. Chemical structure of micafungin.
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Micafungin uptake at 4°C or at 37°C in the presence of choline buffer and 10
M rifampin was measured at various micafungin concentrations and sub-
tracted from total uptake measured at 37°C under control conditions to deter-
mine the net uptake. The net uptake kinetic parameters were determined by
fitting the Michaelis-Menten model in eq. 3 to the data.
Biliary Excretion by Measuring Accumulation (B-CLEAR). SCRH (day
4) or SCHH (day 8) were rinsed with 1.0 ml (12-well plate) or 0.5 ml (24-well
plate) of standard buffer (containing Ca2/Mg2; Plus buffer) or Ca2/Mg2-
free buffer (containing 1 mM EGTA; Minus buffer) and preincubated with the
same buffers for 10 min. All wells were then incubated with 10 M micaf-
ungin in Plus buffer for 10 min. For conditions with modulators (inhibitors),
hepatocytes were treated during the preincubation phase as well as during the
incubation phase with taurocholate (50 and 100 M), nefazodone (25 M),
GF120918 (1 and 10 M), fumitremorgin C (10 M), CDFDA (100 M), or
MK571 (25 M). After the incubation, hepatocytes were rinsed rapidly three
times with 1 ml of ice-cold Plus buffer. After rinsing, micafungin was ex-
tracted from the cells  bile (for hepatocytes incubated in Plus buffer) and
cells (for hepatocytes incubated in Minus buffer), and analyzed as described
above.
Biliary Excretion by Measuring Efflux after Preloading Hepatocytes.
SCRH (day 4) or SCHH (day 8) were preincubated for 10 min with Plus buffer
and then incubated with 10 M micafungin in Plus buffer to load hepatocytes
with micafungin (loading phase). Then hepatocytes were rapidly rinsed with
ice-cold Plus buffer, followed by either Plus buffer or Minus buffer at 37°C to
initiate micafungin efflux to the extracellular medium. Incubation with Plus
buffer allows measurement of efflux from the cells across the sinusoidal
membrane only, whereas incubation with Minus buffer allows measurement of
total efflux from the cells across both sinusoidal and canalicular membrane
domains. When the effect of (canalicular) transporter inhibitors on micafungin
efflux was evaluated, they were added during both the loading and efflux phase
to ensure maximal exposure of canalicular transporters to these inhibitors. At
the end of the efflux phase, extracellular media were collected and centrifuged
for 3 min at 10,000 rpm, and micafungin concentrations were determined as
described below. All results were corrected for incubation time (efflux phase)
and protein content.
Determination of Micafungin by HPLC Coupled with Fluorescence and
UV Detection. Micafungin and diclofenac (internal standard) were separated
by HPLC using a C8 XTerra column (3  100 mm, 3.5 m; Waters, Milford,
MA); a linear gradient of mobile phase A:B (v/v) was used starting from 70:30
at 0 min to 5:95 in 9 min at a flow rate of 0.5 ml/min, where A was 5 mM
ammonium acetate with 0.1% formic acid, pH 4.0, and B was acetonitrile with
0.1% formic acid. Micafungin was detected by fluorescence emission at 464
nm (excitation at 273 nm), and diclofenac was detected by UV at 280 nm; the
retention times were 5.5 min for micafungin and 6.3 min for diclofenac. The
method was linear for a micafungin concentration range of 0.1 to 5 M.
Accuracy and precision of the method were 12 and 3.3% for 0.3 M and 0.2
and 2.8% for 2.5 M, respectively.
Data Analysis. IC50 values were determined using WinNonlin (version 4)
software by nonlinear regression according to eq. 1:
E  Emax  1  CC  IC50 (1)
Nonlinear regression analysis using WinNonlin was applied to determine the
Michaelis-Menten uptake kinetics parameters (Km and Vmax) and the kinetic




 Cld  C (2)
where v represents the experimental uptake rate and C the micafungin con-
centration. The saturable uptake rate was calculated using eq. 3 after subtract-





Saturable uptake clearance (Vmax/Km) was added to the nonsaturable uptake
clearance (Cld) to obtain total in vitro Cluptake, which was used to predict in
vivo Clplasma (Table 2). The biliary excretion index (BEI) (percentage) and in
vitro intrinsic biliary clearance, Clbiliary (milliliters per minute per milligram
protein), were calculated with B-CLEAR technology (Qualyst, Inc., Research









where AUC medium was determined as the product of the incubation time and
extracellular concentration. The in vitro intrinsic Clbiliary and intrinsic Cluptake
(milliliters per minute per milligram protein) values were scaled to kilograms
of body weight using the scaling values listed in Table 2. In the absence of
albumin during in vitro incubations, unbound intrinsic Clbiliary (intrinsic Clbili-
ary) and unbound intrinsic Clplasma (intrinsic Clplasma) were assumed to corre-
spond to in vitro intrinsic Clbiliary (eq. 5) and in vitro intrinsic Cluptake,
respectively. The predicted in vivo Clbiliary and Clplasma values were estimated
according to the well stirred model of hepatic disposition (eqs. 6 and 7),
assuming a micafungin blood/plasma concentration ratio of 1.
Predicted Clbiliary 
QH  fu  intrinsic Clbiliary
QH  fu  intrinsic Clbiliary
(6)
Predicted Clplasma 
QH  fu  intrinsic Clplasma
QH  fu  intrinsic Clplasma
(7)
where QH represents the hepatic blood flow rate and ƒu the fraction of unbound
drug (Table 2).
Statistical Analysis. Statistical analysis of the data was performed using
one-way analysis of variance followed by a Dunnett’s post test to compare
micafungin disposition in inhibitor-treated hepatocytes versus control. Levels
(p  0.05, p  0.01, and p  0.001) of statistically significant inhibition of
micafungin uptake or efflux compared with control values are clarified in the
figure legends.
Results
Micafungin Uptake in Sandwich-Cultured Hepatocytes. The
10-min mean  S.D. cellular uptake of micafungin in day 1 SCRH
and day 6 SCHH was 280  14 pmol/mg protein/min (three different
hepatocyte preparations in triplicate) and 198  26 pmol/mg protein/
min (two different donors in triplicate), respectively. Micafungin
hepatocyte uptake was decreased by 70 to 80% compared with control
values when incubations were performed at 4°C, a condition in which
active transport processes are almost completely absent (Fig. 2). The
cellular uptake of micafungin also was inhibited by 45 to 55% in the
presence of Na-free (choline) buffer, a treatment known to specifi-
cally affect Na-dependent uptake (mediated by NTCP/Ntcp) of bile
acids. In the presence of 100 M taurocholate (a substrate for NTCP/
Ntcp), micafungin uptake was inhibited by 53 and 63% in SCRH and
SCHH, respectively. As shown in Fig. 2, modest inhibition (by
20–25%) was observed with 10 M rifampin (inhibitor of the Na-
independent transporter family, OATP/Oatp).
The NTCP/Ntcp substrate taurocholate inhibited micafungin (10
M; 10 min; Plus buffer) uptake in SCRH in a concentration-
dependent manner with an IC50 value of 73.7  8.4 M (Fig. 3A). In
contrast, taurocholate (2.5 M) uptake was inhibited by micafungin
with an IC50 value of 138.4  16.0 M (Fig. 3B).
Concentration-dependent uptake of micafungin in rat (Fig. 4A) and
human (data not shown) hepatocytes could be described by eq. 2 (see
Materials and Methods), reflecting a combination of a saturable
(Michaelis-Menten) process and a linear, nonsaturable process. Ki-
netic parameters (Table 1) describing active micafungin uptake were
40  5 M (Km) and 814  248 pmol/(min  mg protein) [Vmax] in
human hepatocytes, whereas a Km of 39  6 M and a Vmax of 591 
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24 pmol/(min  mg protein) were obtained in rat hepatocytes (Fig. 4A).
The calculated intrinsic clearance (Vmax/Km) values for active mica-
fungin uptake were 20.5  2.2 and 15.2  4.4 l/(min  mg protein)
in human and rat hepatocytes, respectively. Corresponding values for
Cld, reflecting linear, nonsaturable uptake kinetics, were estimated
to be 3.3  0.5 and 3.8  0.3 l/(min  mg protein), respectively
(Table 1).
The contribution of both active and passive mechanisms to micaf-
ungin uptake in hepatocytes is supported further by the observation
that nonsaturable uptake occurred in the presence of active uptake
inhibitors (Na-free buffer mixed with rifampin) or at 4°C in SCRH.
Saturable (active) uptake in SCRH was determined by subtracting the
4°C uptake profile from total uptake as shown in Fig. 4B. The
nonlinear regression analysis of this active uptake component obeyed
Michaelis-Menten kinetics similar to those generated from the ap-
proach shown in Fig. 4A and Table 1. The nonlinear regression
analysis for the net uptake as a function of micafungin concentration
using the Michaelis-Menten eq. 3 revealed comparable kinetic param-
eters of 49 M for Km and 853 pmol/(min  mg protein) for Vmax,
yielding a value of 17.4 l/(min  mg) for intrinsic clearance (Vmax/
Km) associated with the active process (data not tabulated).
Micafungin Biliary Excretion in SCRH. Accumulation of mica-
fungin in day 4 SCRH was measured in the absence and in the
presence of Ca2/Mg2 in the extracellular medium. The BEI and
Clbiliary were determined by taking into account the accumulation
differences under these conditions and by using eqs. 4 and 5. As
illustrated in Fig. 5A, the mean BEI for micafungin in rat hepatocytes
was 42  7%, compared with a BEI of 60  16% for the well known
substrate taurocholate (data not shown); the BEI of taurocholate has
been reported to be 50 to 80% in SCRH (Annaert et al., 2001; McRae
et al., 2006).
Transporters Involved in Micafungin Biliary Excretion in
SCRH. The biliary excretion of micafungin was inhibited by 90%
with the Bsep inhibitor taurocholate (Marion et al., 2007) and by
50% with GF120918 (10 M), a known inhibitor for P-gp and
BCRP at this concentration (Ahmed-Belkacem et al., 2006) (Fig. 5A).
Coincubation with CDFDA (the diacetate ester of the Mrp2 substrate
carboxydichlorofluorescein) had no effect on the biliary excretion of
micafungin. The possible role of Mrp2 in the biliary excretion of
micafungin was examined further by determining the biliary excretion
of micafungin in sandwich-cultured hepatocytes from TR(/) rats
compared with wild-type rats. The results shown in Fig. 5B were
obtained after preloading the hepatocytes with 10 M micafungin
followed by measuring micafungin efflux under standard conditions
(efflux from cells to extracellular medium only) compared with Ca2/
Mg2-free conditions (efflux from both cells and bile canaliculi to
extracellular medium). These results illustrate that micafungin biliary
excretion was the same in hepatocytes from wild-type and TR(/)
rats. In addition, no effect of the Mrp2 inhibitor MK571 on micafun-
gin biliary excretion could be observed. However, the efflux across
the sinusoidal membrane (“cell”) was slightly higher (20%) in
TR(/) compared with wild-type hepatocytes (p  0.05), whereas
MK571 also showed a slight but statistically significant effect on the
sinusoidal micafungin efflux in wild-type (13% decrease) and
TR(/) (12% decrease) rat hepatocytes.
Micafungin Biliary Excretion in SCHH. After preloading human
hepatocytes with micafungin, efflux corresponding to biliary excre-
tion amounted to 31 to 55% of total efflux (Fig. 6). Nefazodone
FIG. 2. Effect of inhibitors of hepatic drug transporters on micafungin uptake in
sandwich-cultured human and rat hepatocytes. Uptake of micafungin (10 M, 10
min) in sandwich-cultured rat () and human (f) hepatocytes at 4 or 37°C in the
absence and presence of rifampin, choline (Na-free) buffer, or taurocholate is
shown. Bars represent mean relative uptake (as a percentage of control at 37°C) 
S.D. of triplicate determinations. Absolute values for control uptake (100%) were
280  14 pmol/mg protein/min in rat (three different hepatocyte preparations) and
198  26 pmol/mg protein/min in human hepatocytes (two different donors).
Statistical significance: , p  0.05; , p  0.01; , p  0.001, compared with
control uptake in each species.
FIG. 3. Concentration-dependent inhibition of micafungin uptake by taurocholate
and vice versa in sandwich-cultured rat hepatocytes. Inhibition of micafungin (10
M) uptake by taurocholate (A) and inhibition of taurocholate (2.5 M) uptake by
micafungin (B). IC50 values were determined using WinNonlin software. The solid
line represents the best fit to the uptake data according to eq. 1. The data reflect
micafungin uptake expressed as a percentage of the no inhibitor control and are
plotted as a function of inhibitor concentration. The IC50 value for taurocholate
inhibition of micafungin uptake was 73.7  8.4 M (Ki 	 61 M), whereas the IC50
value for micafungin inhibition of taurocholate uptake was 138.4  16.0 M (Ki 	
59 M). Each data point represents the mean  S.D. of three separate measurements
obtained in representative sandwich-cultured rat hepatocyte preparations.
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significantly inhibited micafungin biliary excretion to approximately
10 to 25% of total efflux. A comparable effect was observed for
taurocholate. A much less pronounced or no effect was observed when
micafungin efflux was measured after coincubation with inhibitors for
other canalicular transporters, including GF120918 for P-gp/BCRP,
fumitremorgin C for BCRP, and MK571 for MRP2. The use of 10 M
GF120918 (but not 1 M GF120918) seemed to result in a reduced
canalicular micafungin excretion, an effect that was statistically sig-
nificant in two of three donors. Likewise, the BCRP inhibitor fumit-
remorgin C significantly inhibited micafungin biliary efflux in hepa-
tocyte preparations from one of two donors. Consistent with the
observation in SCRH, the MRP2 inhibitor MK571 did not influence
biliary excretion of micafungin in human hepatocytes. However, a
significant (p  0.05) reduction in the efflux of micafungin across the
sinusoidal membrane could be observed.
Estimation of Plasma and Biliary Clearance of Micafungin in
Human and Rat. The intrinsic biliary clearance values, calculated on
the basis of results from in vitro incubations of micafungin with
SCRH and SCHH according to eq. 5 were 18.7  5.1 l/(min  mg
protein) in rat and 13.8  8.5 l/(min  mg protein) in human. Intrinsic
FIG. 4. Micafungin uptake kinetics in sandwich-cultured rat hepatocytes. The val-
ues for initial velocity (10 min) of micafungin cellular uptake in day 1 culture were
plotted against micafungin concentration in the extracellular medium. In A, the
model (see eq. 2) incorporating a saturable (Michaelis-Menten) component and a
linear component was fitted to the data using the Solver function in MS Excel. Each
point represents the mean of three experimental values obtained in a representative
hepatocyte preparation. In B, concentration-dependent uptake of micafungin in
SCRH is shown for total uptake at 37°C in the absence () or presence of rifampin
in choline (Na-free) buffer (f) and uptake at 4°C (Œ); net saturable uptake (E)
represents the difference between uptake at 37 and 4°C. The solid line represents the
best fit of eq. 3 to the uptake data. Each point represents the mean of three
measurements.
TABLE 1
Summary of micafungin saturable and nonsaturable uptake kinetics in SCRH
and SCHH
Mean  S.D. kinetic parameters reflecting micafungin uptake were obtained by nonlinear
regression using a model incorporating both a saturable (Michaelis-Menten) component and a
nonsaturable (linear) component. Taurocholate uptake clearance values in the two SCRH
cultures used here were 22.5  4.8 and 28.5  2.6 l/(min  mg protein).
Kinetic Parameter Rat Human
Km (M) 39  6 40  5
Vmax 
pmol/(min  mg protein) 591  24 814  248
Cld 
l/(min  mg protein) 3.8  0.3 3.3  0.5
Vmax/Km 
l/(min  mg protein) 15.2  4.4 20.5  2.2
FIG. 5. Effect of inhibitors of bile canalicular transporters on micafungin (10 M)
biliary excretion in day 4 SCRH. A, hepatocytes were incubated with 10 M
micafungin for 10 min to determine accumulation of micafungin in cells  bile
canaliculi (u, Plus buffer: contains Ca2/Mg2) or accumulation in cells only (,
Minus buffer: without Ca2/Mg2). Using B-CLEAR technology, biliary excretion
of micafungin was calculated from the difference in accumulation (f) between the
Plus and Minus buffer conditions. In vitro biliary excretion of micafungin was
measured in the absence and presence of taurocholate (100 M), GF120918
(GF918, 10 M), or CDFDA (100 M). Numbers [%] represent the BEI values
calculated according to eq. 4. B, after loading sandwich-cultured hepatocytes
prepared from wild-type (WT) or TR(/) rats with micafungin (10 M) for 10
min, micafungin efflux was determined in Plus buffer [efflux from cell to extracel-
lular medium occurs across sinusoidal membrane only ()] and in Minus buffer
[efflux from cell to extracellular medium occurs across sinusoidal and canalicular
membranes (u)]. Incubations also were conducted in the presence of the Mrp2
inhibitor MK571. Numbers (%) represent relative efflux to bile canaliculi as a
percentage of total efflux. Statistical significance: #, p  0.05; ##, p  0.01 for
biliary excretion, compared with control (A); , p  0.05 for efflux across the
sinusoidal membrane, either in TR(/) compared to WT hepatocytes, or in
hepatocytes treated with MK571 compared to the corresponding untreated hepato-
cytes [WT or TR(/)].
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plasma clearance, calculated from in vitro uptake kinetics of micaf-
ungin (see Materials and Methods), was 19.0 l/(min  mg protein) in
rat and 23.5 l/(min  mg protein) in human. These intrinsic clearance
values were scaled to total body intrinsic clearance values using the
scaling parameters shown in Table 2. In vivo clearance values were
estimated from the micafungin fu and QH in human and rat, along with
the scaled intrinsic clearance values, assuming the well stirred model
for hepatic disposition (see eqs. 6 and 7). Good agreement was found
between observed in vivo plasma clearance values for micafungin in
rat and human and the corresponding calculated values based on in
vitro uptake clearance measurements. In contrast, at the level of
biliary excretion, human in vivo biliary clearance of micafungin was
well predicted on the basis of in vitro data, whereas in vivo rat biliary
clearance was approximately 5-fold overpredicted.
Discussion
Biliary excretion has been reported to account for approximately
90% of micafungin clearance (Hebert et al., 2005a). The relatively
large molecular weight of this antifungal compound and its negatively
charged sulfate function at physiological pH strongly suggest the
involvement of drug transporters both in the hepatic uptake and biliary
excretion of micafungin. Nevertheless, very little is known regarding
the possible role of transporters in hepatobiliary elimination of mica-
fungin in rats (Abe et al., 2008b), and no information is available in
humans. In contrast, for another echinocandin, caspofungin, the active
transport mechanisms possibly mediating its hepatic uptake have been
investigated in experiments that used HeLa cells heterologously ex-
pressing the hepatic OATP isoforms (Sandhu et al., 2005). These
uptake transporters have been suggested to play key roles in the
hepatic elimination of caspofungin. It is also important to understand
the role that transport proteins play in the sinusoidal uptake and
canalicular excretion of micafungin.
To obtain this information in the present study, we used sandwich
cultures of rat and human hepatocytes. Prior investigations have
demonstrated the utility of sandwich-cultured hepatocytes to better
understand the mechanisms governing hepatic uptake and biliary
excretion of endogenous and exogenous compounds (Chandra et al.,
2001; Annaert and Brouwer, 2005; Kemp et al., 2005; McRae et al.,
2006). This in vitro model allows simultaneous assessment of hepatic
uptake and biliary excretion, and the relative contributions of each
process to overall hepatobiliary disposition can be derived.
Our in vitro data on micafungin uptake show that, like caspofungin,
transporters of the OATP/Oatp family in both human and rat hepato-
cytes mediate micafungin uptake. However, OATPs/Oatps played a
modest role compared with the Na-dependent micafungin uptake,
which is a process mediated by NTCP/Ntcp. Micafungin uptake was
inhibited most profoundly by taurocholate or Na depletion in both
SCRH and SCHH. In SCRH, the concentration-dependent inhibition
of taurocholate uptake by micafungin (IC50 	 138 M) (Fig. 3B) was
evaluated; on the basis of the Cheng and Prusoff (1973) equation, the
estimated Ki for inhibition of taurocholate uptake by micafungin was
59 M. A comparable value (Ki 	 61 M) was obtained for inhibition
of micafungin uptake by taurocholate. Taken together, these data
support the hypothesis that NTCP/Ntcp plays a predominant role in
micafungin uptake in both rat and human hepatocytes. This result is
somewhat remarkable because NTCP is still thought to be quite
specific for mediating hepatic uptake of bile acids. Indeed, only a few
nonbile acid substrates for NTCP/Ntcp have been reported, including
estrone-3-sulfate (Schroeder et al., 1998; Kullak-Ublick et al., 2000)
and rosuvastatin (Ho et al., 2006). The structure of these previously
identified nonbile acid substrates, as well as that of micafungin,
features a sulfate or sulfonamide functional group.
Using B-CLEAR technology (Liu et al., 1999a; Hoffmaster et al.,
2004; Ghibellini et al., 2007), we showed pronounced in vitro biliary
excretion of micafungin, both in SCRH (by accumulation experi-
ments) (Fig. 5) and in SCHH (by efflux experiments after preloading
hepatocytes; see Materials and Methods) (Fig. 6). The suitability of
the three batches of SCHH used in the present study to determine
biliary excretion of micafungin was assessed by measuring the biliary
excretion index of the established substrate taurocholate, which was
found to be 62  15%. This result compares well with the previously
reported BEI of taurocholate in sandwich-cultured human hepatocytes
of 56% (Ghibellini et al., 2007). In SCRH, coincubation of micafun-
gin with 100 M taurocholate resulted in a reduction in micafungin
accumulation under standard conditions to the same levels as ob-
served in Ca2-free conditions (Fig. 5A). Taurocholate was also the
FIG. 6. Effect of inhibitors of bile canalicular transporters on micafungin biliary
excretion in three batches of sandwich-cultured human hepatocytes. After sand-
wich-cultured human hepatocytes were loaded with micafungin (10 M) for 10
min, micafungin efflux was determined in Plus buffer [efflux from cell to
extracellular medium occurs across sinusoidal membrane only ()] and in
Minus buffer [efflux from cell to extracellular medium occurs across sinusoidal
and canalicular membranes (u)]. Efflux also was measured in the presence of
inhibitors as indicated; MK571, taurocholate, and nefazodone were used at 25,
100, and 25 M, respectively. Bars represent mean  S.D. (n 	 3) efflux of
triplicate measurements in each batch. Numbers in parentheses indicate the
percentage of biliary efflux relative to total efflux (from cell  bile) for each
treatment. Statistical significance compared with control: , p  0.05 for the
efflux across sinusoidal membrane; #, p  0.05; ##, p  0.01 for biliary
excretion. GF918, GF120918; FTC, fumitremorgin C.
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most effective inhibitor of micafungin biliary excretion in SCHH on
the basis of taurocholate-mediated inhibition of micafungin canalic-
ular efflux from preloaded hepatocytes (Fig. 6). Our in vitro biliary
excretion data with micafungin in SCRH and SCHH support the
primary involvement of BSEP/Bsep in micafungin biliary excretion.
In SCHH, inhibition of micafungin biliary excretion by the BSEP
inhibitor nefazodone (Kostrubsky et al., 2006) provided further evi-
dence for the role of BSEP. The inhibitory effects observed with the
mixed P-gp/BCRP inhibitor GF120918 and the selective BCRP in-
hibitor fumitremorgin C in SCHH suggests that BCRP, but not P-gp,
plays some role in micafungin biliary excretion. The latter observation
is consistent with a previous report that micafungin is not a substrate
for P-gp (Sakaeda et al., 2005).
In SCRH, we specifically investigated the possible role of Mrp2 in
the biliary excretion of micafungin by conducting in vitro biliary
excretion experiments in sandwich-cultured hepatocytes from
TR(/) rats, which are deficient in functional Mrp2. In vitro mica-
fungin biliary excretion in these mutant rats was unaltered compared
with that in wild-type rats. Furthermore, in vitro micafungin biliary
excretion was unaffected by the presence of the Mrp2 substrate
carboxydichlorofluorescein or the Mrp2 inhibitor MK571. These data
suggest that either Mrp2 does not play a significant role in micafungin
biliary excretion in rats, or that another canalicular protein is able to
completely compensate for the absence of Mrp2. Our observation is
inconsistent with the recent in vivo study by Abe et al. (2008b), who
reported that micafungin biliary clearance was reduced (by approxi-
mately 60%) in TR(/) rats, suggesting an important role of Mrp2
in the biliary excretion of micafungin in normal rats in vivo. However,
apart from undetectable Mrp2 levels, Abe et al. (2008c) showed that
Bcrp expression was reduced markedly in TR(/) rats, indicating
that reduced biliary drug clearance in these mutant rats is not neces-
sarily due to Mrp2 involvement. Alternatively, discrepancies between
our in vitro data and previous in vivo data on the involvement of Mrp2
in biliary excretion of micafungin also could be caused by altered
transporter expression levels in cultured hepatocytes compared with
the liver in vivo. It is also noteworthy that the expression and function
of Mrp3 are enhanced in TR(/) rats compared with wild-type rats
(Xiong et al., 2002). Thus, the decrease in biliary clearance of mica-
fungin in TR(/) rats (Abe et al., 2008b) also might be caused by
increased Mrp3-mediated sinusoidal efflux rather than decreased
Mrp2-mediated canalicular efflux of micafungin. In the present study,
we also observed slight but significant reductions in sinusoidal mica-
fungin efflux upon coincubation with the Mrp2/Mrp3 inhibitor
MK571, which further supports that a sinusoidal efflux transporter
(such as Mrp3) but not Mrp2 (localized at the canalicular membrane)
plays a role in micafungin disposition in SCRH. Chemical inhibition
experiments with MK571 in SCHH (Fig. 6) also confirm that in
human liver MRP2 is not extensively involved in micafungin biliary
excretion or that other canalicular protein(s) are able to compensate
for and maintain biliary excretion of micafungin. Given the very
limited overall metabolism of micafungin (Hebert et al., 2005a; As-
tellas Pharma Inc., 2006) as well as the absence of any conjugates
(phase II metabolites are typical MRP2 substrates), it is also unlikely
that MRP2 plays a significant role in elimination of micafungin
metabolites. Reduced micafungin efflux across the sinusoidal mem-
brane of SCHH was observed in the presence of MK571. This may
support a role for a sinusoidal efflux transporter, such as MRP3, in
micafungin disposition in SCHH. However, it should be noted that the
effect of MK571 on micafungin efflux also may be related to de-
creased accumulation of micafungin during the loading phase. Recent
reports (Matsson et al., 2009) suggest poor specificity of MK571,
whereby transporters other than MRPs, such as OATP (Janneh et al.,
2010), were affected by MK571. Nevertheless, given the rather lim-
ited role of OATPs in micafungin uptake, it remains unlikely that
MK571 would cause a substantial reduction in micafungin uptake
during the loading phase.
In the same in vivo rat study involving micafungin, Abe et al.
(2008b) showed that the systemic clearance of micafungin in normal
rats was reduced after intravenous cyclosporine A administration.
Whereas cyclosporine A is an inhibitor of MRP2/Mrp2, it is also an
inhibitor of NTCP (Mita et al., 2006), OATPs/Oatps (Shitara et al.,
2009), and BSEP/Bsep (Mita et al., 2006). Accordingly, in the context
of our in vitro data, cyclosporine A is likely to decrease micafungin
systemic clearance by inhibiting Ntcp and/or Oatp-mediated uptake of
micafungin and/or by inhibiting Bsep-mediated (and Bcrp-mediated)
biliary excretion in rats. However, there is little evidence for Mrp2
TABLE 2
Calculation of in vivo plasma and biliary clearance of micafungin based on in vitro data obtained in rat and human hepatocytes
In vitro Cl values and in vivo predicted Cl values represent mean  S.D. (n 	 2–3 batches of hepatocytes). Intrinsic Cl values were generated as described under Materials and Methods.
Intrinsic uptake clearance was calculated by combining the saturable and nonsaturable clearance values that are listed in Table 1. Intrinsic biliary clearance was determined using B-CLEAR
technology (Liu et al., 1999). Scaled intrinsic clearance and predicted in vivo clearance were calculated as described by Abe et al. (2008c) using eq. 6 (well stirred model of hepatic drug
clearance). In vivo biliary clearance in humans was obtained by multiplying total clearance with the fraction of a micafungin dose eliminated in bile (based on a human mass balance study
with radiolabeled micafungin; 71% of the eliminated dose was recovered in bile/feces, whereas only trace amounts of metabolites were detected).
Physiological Parameters and Scaling Factors Rat Human
fu 0.003
a 0.004b
Hepatic protein content mg protein/g of liver 200c 71d
Relative liver weight g liver/kg b.wt. 40c 26d
QH 
ml/(min  kg) 40
c 21d,f
In vivo plasma clearance 
ml/(min  kg) 1.25g 0.229h
In vitro intrinsic uptake clearance 
ml/(min  mg protein) 0.0190  0.0044 0.0235  0.0016
Intrinsic uptake clearance 
ml/(min  kg) 152.4  35.3 43.38  2.95
Calculated in vivo plasma clearance 
ml/(min  kg) 0.447  0.104 0.175  0.012
In vivo biliary clearance 
ml/(min  kg) 0.085g 0.16e
In vitro intrinsic biliary clearance 
ml/(min  kg) 0.019  0.005 0.014  0.009
Intrinsic biliary clearance 
ml/(min  kg) 149.3  41.1 25.54  15.69
Calculated in vivo biliary clearance 
ml/(min  kg) 0.438  0.120 0.101  0.062
a Data from Abe et al. (2008a).
b Data from S. B. Yanni, P. B. Smith, D. K. Benjamin, P. Augustijns, D. R. Thakker, and P. P. Annaert, manuscript submitted for publication.
c Data from Abe et al. (2008c).
d Data from Ghibellini et al. (2007).
e Data for Mycamine (micafungin sodium) from Astellas Pharma US Inc. 
full prescribing information (§12.3. Pharmacokinetics), http://www.astellas.us/docs/mycamine.pdf.
f Data from Björkman (2005).
g Data from Abe et al. (2008b).
h Data from Wiederhold and Lewis (2007).
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being involved in this drug interaction, or in micafungin hepatobiliary
disposition in rats.
In human liver, the role of NTCP/BSEP in the hepatobiliary elim-
ination of micafungin can explain observed clinical interaction data
reported by Hebert et al. (2005a) with cyclosporine A, which in-
creased micafungin plasma AUC; however, the underlying mecha-
nism has not been fully described. Our in vitro data support the
inhibition of NTCP and/or BSEP by cyclosporine A (as previously
described by Mita et al., 2006) as a primary mechanism to explain this
clinical drug interaction. Another clinical implication of our findings
is that extensive micafungin biliary excretion, mediated by BSEP, is
responsible for its therapeutic success in the treatment of candidal
cholecystitis (Maruyama et al., 2009). This finding also suggests that
knowledge of transporter-mediated drug disposition mechanisms
could provide a rational basis for establishing targeted drug delivery
to specific tissues.
Comparison of our in vitro data for rat and human hepatocytes
reveals a remarkable agreement between both species when the trans-
porters involved in micafungin hepatobiliary disposition are consid-
ered. This observation contrasts with the pronounced interspecies
differences that generally have been reported, not only for drug-
metabolizing enzymes but also for hepatic drug transporters involved
in drug elimination (Leslie et al., 2007) and interactions (Ye et al.,
2010). To assess whether this qualitative species similarity in micaf-
ungin disposition also is reflected at the quantitative level, in vivo
plasma and biliary clearance of micafungin in rats and humans was
calculated based on the in vitro uptake and biliary excretion data
obtained in sandwich-cultured rat and human hepatocytes (Table 2).
There was general agreement between the observed plasma clearance
values and those predicted based on in vitro hepatic uptake data. In
contrast, in vivo biliary clearance values in humans were well pre-
dicted by in vitro biliary excretion data obtained in SCHH but were
overpredicted in the rat. This may be due to the existence of metabolic
clearance pathways for micafungin in rat liver in vivo, the function-
ality of which may not be fully reflected in day 4 SCRH. Reduced
drug-metabolizing enzyme activities in SCRH compared with in vivo
levels have been reported previously (Liu et al., 1999a). Comparison
of the in vivo biliary clearance values with in vivo plasma clearance
values (Table 2) suggests that biliary excretion of micafungin rather
than hepatic uptake is rate-limiting for its hepatic elimination in
humans.
In conclusion, using sandwich-cultured rat and human hepatocytes,
we have characterized the micafungin hepatic uptake kinetics and
identified NTCP/Ntcp and BSEP/Bsep as important mediators of
micafungin hepatocyte uptake and biliary excretion, respectively, in
both species. Figure 7 depicts the various mechanisms underlying the
hepatobiliary disposition of micafungin. It remains to be investigated
to what extent the sharing of NTCP/BSEP between micafungin and
bile acids may be responsible for side effects in patients receiving
micafungin therapy. In this context, it is noteworthy that a warning for
hepatotoxicity has been included in the micafungin label, and that a
recent case report (Anonymous, 2009) supports a possible association
between hepatotoxicity and the use of micafungin. More pronounced
inhibition of BSEP (over NTCP) by micafungin theoretically could
lead to cholestasis, and this mechanism has been associated with the
hepatotoxicity of several drugs including bosentan (Leslie et al.,
2007). As of today, however, there are no reports that micafungin
causes cholestasis in the clinic, which might be explained by the fact
that micafungin inhibits NTCP to approximately the same extent as
BSEP. Reported total plasma concentration maxima of micafungin in
humans are in the range of 5 to 8 M, whereas protein binding is very
high (99.5%). Given a Ki value of 59 M for inhibition of tauro-
cholate uptake by micafungin in rat liver, and assuming a comparably
high Ki applies for inhibition of human NTCP, the interference of
micafungin with bile acid uptake may not be clinically relevant.
Furthermore, coadministration of micafungin with other drugs (e.g.,
cyclosporine A) that affect NTCP/BSEP with micafungin also will
determine the clinical relevance of potential interactions between
micafungin and bile acid homeostasis and elimination. It is clear that
future in vitro experiments in sandwich-cultured hepatocytes using
clinically relevant drug combinations may support the rational pre-
vention of possible drug interactions and toxicity in patients taking
multiple drugs including micafungin.
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